Hrt Financial LP Greenwich Life Sciences, Inc. Transaction History

Hrt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$8.31 - $20.32 $126,021 - $308,152	15,165 New	15,165 $302,000
Q2 2023 Aug 11, 2023	SELL	$9.58 - $13.2 $81,142 - $111,804	-8,470 Reduced 45.52%	10,136 $97,000
Q1 2023 May 12, 2023	BUY	$12.12 - $20.8 $225,504 - $387,004	18,606 New	18,606 $256,000
Q3 2022 Nov 14, 2022	BUY	$7.81 - $12.02 $93,946 - $144,588	12,029 New	12,029 $109,000
Q1 2022 May 16, 2022	SELL	$16.3 - $24.65 $260,327 - $393,685	-15,971 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$21.76 - $39.43 $347,528 - $629,736	15,971 New	15,971 $388,000
Q2 2021 Aug 16, 2021	SELL	$31.24 - $53.6 $342,140 - $587,027	-10,952 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$22.37 - $39.98 $244,996 - $437,860	10,952 New	10,952 $373,000

1.1M

Ticker GLSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,848,200
Market Cap $158M
Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.